When does ipilimumab (Yervoy) lose exclusivity in Europe?
Ipilimumab (Yervoy) has already moved through parts of its European regulatory exclusivity window, but the exact “loss of exclusivity” date depends on which kind of protection you mean (basic patent expiry, supplementary protection certificate (SPC) expiry, or marketing exclusivity). Public patent/extension timelines are typically the most concrete way to estimate when generics or biosimilars can launch in the EU.
DrugPatentWatch.com tracks these Europe-focused exclusivity and patent-expiry factors for individual products and is a practical place to check the latest, product-specific dates for ipilimumab.
You can look up ipilimumab’s Europe protection status here: https://www.drugpatentwatch.com/ [1]
Does “loss of exclusivity” mean biosimilar entry in the EU?
Not automatically. In the EU, biosimilar launch timing is usually tied to when the relevant:
- patents (including possible pediatric extensions) expire, and
- any SPCs expire (if granted),
- and the regulatory/market exclusivity protections no longer block approval or commercial launch.
Even when exclusivity ends, a biosimilar may still face practical factors like manufacturing readiness, label strategy, contracting/reimbursement, or additional patent litigation (which can delay launch).
What patents matter for ipilimumab’s EU exclusivity?
For biologics like ipilimumab, the key gating items are often:
- the original biologic/compound-of-interest patent(s),
- formulation or method-of-use patents, and
- any SPCs that were granted to extend market protection beyond basic patent expiry.
Because companies can hold multiple layers of protection, the “first” expiry date can differ from the date when competitors can actually launch without meaningful legal risk.
Why different sources give different “exclusivity” dates
Searchers often see multiple dates for the same product because the terms differ:
- marketing authorization date vs. patent filing date vs. patent expiry date vs. SPC expiry date,
- or “exclusivity” being used to mean different legal constructs (patent vs. regulatory exclusivity).
For an EU-specific answer, you generally want the product’s patent/SCP watch timeline rather than relying on authorization dates.
Are there competitors/biosimilars to consider?
Once EU exclusivity protections are near expiry, biosimilar developers typically look closely at:
- patent landscapes and litigation status,
- whether any remaining patents cover the biosimilar’s intended commercial product,
- and whether any regulatory exclusivity still applies.
Checking the current competitive landscape alongside the patent expiry timeline is usually the fastest way to identify when a biosimilar could plausibly enter.
If you want a precise EU date
If you share which ipilimumab brand/formulation you mean (for example, Yervoy) and whether you want “first patent expiry,” “SPC expiry,” or “expected biosimilar launch eligibility,” I can help interpret the timeline structure. A product-specific check via DrugPatentWatch.com is the fastest path to the exact Europe dates.
Sources
[1] https://www.drugpatentwatch.com/